Background. Women over 70 with breast cancer have poorer one-year survival and present at a more advanced stage than younger women. Promoting early symptomatic presentation in older women may reduce stage cost effectively and is unlikely to lead to overdiagnosis. After examining efficacy in a randomised controlled trial, we piloted a brief health professional-delivered intervention to equip women to present promptly with breast symptoms, as an integral part of the final invited mammogram at age ~70, in the English National Health Service Breast Screening Programme. Methods. We trained mammographers, who then offered the intervention to older women in four breast screening services. We examined breast cancer awareness at baseline and one month in women receiving the intervention, and also in a service where the intervention was not offered. Results. We trained 27 mammographers to deliver the intervention confidently to a high standard. Breast cancer awareness increased 7-fold at one month in women receiving the intervention compared with 2-fold in the comparison service (odds ratio 15.2, 95% confidence interval 10.0 to 23.2). Conclusions. The PEP Intervention can be implemented in routine clinical practice with a potency similar to that achieved in a randomised controlled trial. It has the potential to reduce delay in diagnosis for breast cancer in older women. 1. Introduction Older women with breast cancer have poorer one-year relative survival than younger women [1] and are more likely to be diagnosed with advanced stage of disease [2]. Older age is a risk factor for delay in presentation in breast cancer [3]. Women over the age of 73 are not routinely invited for screening on the English National Health Service (NHS) Breast Screening Programme; most women with breast cancer of this age group therefore present symptomatically. We have developed a brief intervention to promote early symptomatic presentation of breast cancer in older women (the Promoting Early Presentation (PEP) Intervention) [4]. It is a scripted one-to-one intervention, delivered to an older woman in a positive, collaborative, and motivational style by a health professional, providing the knowledge, motivation, confidence, and skills to present promptly on discovering a breast symptom. It is supported by a booklet which women are given to take home. The PEP Intervention increased breast cancer awareness fourfold compared with usual care for up to two years in a randomised controlled trial, in which it was delivered by research health professionals [5, 6], and the effect was sustained
References
[1]
H. M?ller, F. Sandin, F. Bray et al., “Breast cancer survival in England, Norway and Sweden: a population-based comparison,” International Journal of Cancer, vol. 127, no. 11, pp. 2630–2638, 2010.
[2]
G. Lyratzopoulos, G. A. Abel, J. M. Barbiere, C. H. Brown, B. A. Rous, and D. C. Greenberg, “Variation in advanced stage at diagnosis of lung and female breast cancer in an English region 2006–2009,” British Journal of Cancer, vol. 106, no. 6, pp. 1068–1075, 2012.
[3]
A. Ramirez, A. M. Westcombe, C. C. Burgess, S. Sutton, P. Littlejohns, and M. A. Richards, “Factors influencing delayed presentation of breast cancer: a systematic review,” The Lancet, vol. 353, no. 9159, pp. 1127–11131, 1999.
[4]
C. C. Burgess, A. M. Bish, H. S. Hunter et al., “Promoting early presentation of breast cancer: development of a psycho-educational intervention,” Chronic Illness, vol. 4, no. 1, pp. 13–27, 2008.
[5]
L. J. L. Forbes, L. Linsell, L. Atkins et al., “A promoting early presentation intervention increases breast cancer awareness in older women after 2 years: a randomised controlled trial,” British Journal of Cancer, vol. 105, no. 1, pp. 18–21, 2011.
[6]
L. Linsell, L. J. L. Forbes, M. Kapari et al., “A randomised controlled trial of an intervention to promote early presentation of breast cancer in older women: effect on breast cancer awareness,” British Journal of Cancer, vol. 101, no. 2, pp. S40–S48, 2009.
[7]
J. Austoker, C. Bankhead, L. J. L. Forbes et al., “Interventions to promote cancer awareness and early presentation: systematic review,” British Journal of Cancer, vol. 101, no. 2, pp. S31–S39, 2009.
[8]
G. C. Wishart, J. Warwick, V. Pitsinis, S. Duffy, and P. D. Britton, “Measuring performance in clinical breast examination,” British Journal of Surgery, vol. 97, no. 8, pp. 1246–1252, 2010.
[9]
L. Linsell, L. J. L. Forbes, C. Burgess, M. Kapari, A. Thurnham, and A. J. Ramirez, “Validation of a measurement tool to assess awareness of breast cancer,” European Journal of Cancer, vol. 46, no. 8, pp. 1374–1381, 2010.
[10]
J. S. Routman, J. H. Willig, A. O. Westfall et al., “Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care,” Clinical Infectious Diseases, vol. 50, no. 4, pp. 574–584, 2010.
[11]
R. van der Lem, N. J. van der Wee, T. van Veen, and F. G. Zitman, “Efficacy versus effectiveness: a direct comparison of the outcome of treatment for mild to moderate depression in randomized controlled trials and daily practice,” Psychotherapy and Psychosomatics, vol. 81, no. 4, pp. 226–234, 2012.
[12]
R. Thomson, “Evidence based implementation of complex interventions,” British Medical Journal, vol. 339, Article ID b3124, 2009.
[13]
B. K. Nallamothu, R. A. Hayward, and E. R. Bates, “Beyond the randomized clinical trial. The role of effectiveness studies in evaluating cardiovascular therapies,” Circulation, vol. 118, no. 12, pp. 1294–1303, 2008.
[14]
L. J. L. Forbes, L. Atkins, A. Thurnham, J. Layburn, F. Haste, and A. J. Ramirez, “Breast cancer awareness and barriers to symptomatic presentation among women from different ethnic groups in East London,” British Journal of Cancer, vol. 105, pp. 1474–1479, 2011.
[15]
K. Robb, S. Stubbings, A. Ramirez et al., “Public awareness of cancer in Britain: a population-based survey of adults,” British Journal of Cancer, vol. 101, no. 2, pp. S18–S23, 2009.
[16]
M. A. Richards, A. M. Westcombe, S. B. Love, P. Littlejohns, and A. J. Ramirez, “Influence of delay on survival in patients with breast cancer: a systematic review,” The Lancet, vol. 353, no. 9159, pp. 1119–1126, 1999.
[17]
M. P. Coleman, D. Forman, H. Bryant et al., “Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the international cancer benchmarking partnership): an analysis of population-based cancer registry data,” The Lancet, vol. 377, no. 9760, pp. 127–138, 2011.
[18]
Office for National Statistics, Cancer Registration Statistics England 2008, Office for National Statistics, Newport, UK, 2010.